SM said there are 3 concerns investors are asking about... a plan for raising cash, the pathway for Fabry, and the options for CAR-Tregs... his follow-up sounded like he's hoping to partner both Fabry and CAR-Tregs to provide that future funding

and "without a doubt, the key catalyst for Sangamo is the Fabry meeting with FDA"... if that meeting is "without a doubt", any other potential catalysts can't be very market moving

he also said "I don't see us showing any more Fabry data until next year" and "I haven't seen the Hemo A P3 results"... that was surprising... so now it's a continued lack of clarity and/or action re funding and a "wait til next year" for any update on its 2 lead assets... IOW, just trust SM because he said "there is a bright future for Sangamo"

BOL... and watch what he does, not what he says :-)